Clinical Trials Logo

Glioblastoma Multiforme (GBM) clinical trials

View clinical trials related to Glioblastoma Multiforme (GBM).

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04587830 Recruiting - Clinical trials for Glioblastoma Multiforme (GBM)

ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

GBM
Start date: September 14, 2020
Phase: Phase 1
Study type: Interventional

Assess safety and tolerability of ADI-PEG 20 in combination with radiotherapy and Temozolomide in newly diagnosed GBM

NCT ID: NCT03213002 Recruiting - Cancer Clinical Trials

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

CAPTEM
Start date: June 13, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.